search.noResults

search.searching

note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
SCOTTISH HOSPITAL NEWS NEW TREATMENT IMPROVES CONTROL


OF DIABETES AT MEALTIMES A new fast-acting mealtime insulin for adults living with type 1 or type 2 diabetes has been launched in the UK. Fiasp® (fast- acting insulin aspart) is an innovative formulation that more closely matches the natural physiological insulin response of a person without diabetes, after meals, compared with the rapid-acting insulin, NovoRapid® (insulin aspart). Fast- acting insulin aspart will be made available to the NHS at no additional cost versus conventional insulin aspart and may help patients tighten the control of their blood sugar levels after meals.


‘Managing blood sugar levels around mealtimes can be challenging for those living with diabetes,’ explains Professor David Russell-Jones, primary investigator for onset 1, Consultant Physician at the Royal Surrey County Hospital, and Professor of Diabetes and Endocrinology at the University of Surrey. ‘Mealtime insulins are usually


taken by patients before eating to effectively reduce the meal- associated rise in blood sugar.’


Fast-acting insulin aspart is absorbed faster than insulin aspart, appearing twice as fast in the bloodstream after injection versus conventional insulin aspart, which leads to improved glycaemic control after meals. Fast-acting insulin aspart significantly improves overall glycaemic control in patients with type 1 diabetes and had comparable overall glycaemic control in patients with type 2 diabetes versus insulin aspart. Mealtime glucose control (ie, blood sugar levels after meals) was also significantly improved in patients with type 1 or type 2 diabetes at one hour after eating versus insulin aspart. These outcomes were achieved without a significant difference in the overall rate of severe or confirmed hypoglycaemia compared with insulin aspart.


BLOOD, SWEAT AND TEARS: NEW WAYS TO MONITOR GLUCOSE LEVELS IN DIABETES


People with diabetes have traditionally self-monitored their glucose levels using disposable biosensors and invasive sampling techniques. While this industry has been one of the success stories of the printed electronics industry, worth around $6 billion today, profitability is falling as government reimbursement models are changing and strain is put on both consumers and manufacturers. However, new methods of glucose monitoring are emerging and these technologies have been comprehensively analysed comprehensively in a new report from IDTechEx Research entitled ‘Technologies for Diabetes Management 2017-2027: Forecasts, Players, Opportunities


Glucose is present in many biological fluids at varying levels and a wide range of players are investigating ways to utilise these fluids for long term glucose monitoring. The most successful of these ventures have been in measuring glucose in interstitial fluid, where continuous glucose monitors are receiving regulatory approval and adoption by people with diabetes across Europe


and North America.


Continuous glucose monitors consist of a wearable sensor and a receiver (which in many cases can be a smartphone). The sensor consists of a microneedle which sits just under the skin and records glucose levels at regular intervals and transmits these to the reader via Bluetooth or NFC technology. Sensors last an average of 6 days, and currently require regular calibration with blood based biosensors.


Companies are investigating the potential for glucose testing in sweat, tears and saliva with varying levels of success and these projects are also analysed in the new IDTechEx report.


Such long-term monitoring solutions will enable the creation of an artificial pancreas - a device that can monitor glucose levels and administer controlled doses of insulin accordingly- leading to fully automated diabetes control. The first such device received regulatory approval in late 2016 and is expected for release later this year.


DELIVERING INTEGRATED SOLUTIONS


Alliance Healthcare – the UK’s leading distributorand wholesaler of pharmaceutical, medical and healthcare products.


Our business was founded by local pharmacists, to support community pharmacy. Seventy years on, our commitment remains the same, but the healthcare environment we work in is changing quickly. That’s why, using our expertise and working in partnership with pharmacy, hospitals and dispensing doctors, we’re focused on developing and delivering integrated solutions and innovations, to improve healthcare in our communities and help your business grow.


With end-to-end involvement right across the supply chain, from factory gate to patient and every point in between, we are committed to using our extensive network and years of expertise to deliver, not only medicines, but added-value services to improve healthcare in our communities.


To find out more about the solutions we can offer, visit our website www.alliance-healthcare.co.uk or call us on 020 8391 2323.


Member of Walgreens Boots Alliance


Alliance Healthcare_Scottish Pharmacist_2016_Feb_1/2pAdvert_02.indd 1


02/02/2016 12:31


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56